Market Size of Asia Pacific Blister Packaging Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 6.50 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
APAC Blister Packaging Market Analysis
The Asia-Pacific Blister Packaging Market is expected to register a CAGR of 6.5% during the forecast period 2021-2026. The outbreak of new diseases, growth in regulatory norms, focus on population health management, inventions, more informed customers, and growth in OTC drugs, have augmented the growth of blister packaging in the region.
- Increasing pressure on pharmaceutical companies to manufacture more medicines to be made available for patients, owing to a rise in diseases and stringent governmental regulations against counterfeit drugs, are among the major factors propelling the market.
- Moreover, factors like product integrity and extended shelf life are highly necessary for the pharmaceutical sector, considering that most consumers store their drugs in a temperature variant atmosphere that can be harmful to unprotected medicines.
- There is also a growing demand for pharmaceutical and personal care products in the region where considerable consumer expenditure is increasing for both pharmaceutical and personal care products. Products, such as capsules, lozenges, sterile products, and liquid cosmetics like perfumes
- In the pharmaceutical industry, blister packaging offers a wide range of solutions: among these are PVC, PCTFE, PVDC, and thermoform blisters for less sensitive products or Alu-Alu cold form blisters for Active Pharmaceutical Ingredients (APIs) that are more sensitive. However, unsuitability for heavy items coupled with stringent regulation in developing countries is anticipated to restrain the market growth.
- The outbreak of Covid-19 has boosted the demand for blister packaging in the region as demand from the pharmaceutical industry rose dramatically. For Instance, India will export 285 million tablets of anti-malaria drug hydroxychloroquine (HCQ) to 40 countries and 500 million tablets of paracetamol to 60 countries to fight Covid-19.
